Alphabet-founded research and development company Calico Life Sciences LLC announced on Thursday that the US Food and Drug Administration (FDA) has granted Fast Track Designation for ABBV-CLS-628, an investigational therapy for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).
An anti-PAPP-A human monoclonal antibody, ABBV-CLS-628 was developed by Calico in collaboration with AbbVie Inc (NYSE:ABBV). The therapy is currently in a Phase 2 clinical trial evaluating its safety and efficacy in patients with ADPKD.
ABBV-CLS-628 has completed a Phase 1 study in healthy volunteers in which it was shown to be safe and well tolerated with no significant adverse events reported to be associated with the drug.
The ongoing Phase 2 study is now enrolling across approximately 95 sites globally. Participants receive intravenous ABBV-CLS-628 or placebo every 4 weeks for 92 weeks, with safety follow-up for up to 15 weeks. This study is designed to evaluate the safety, tolerability, and potential efficacy of ABBV-CLS-628 in slowing disease progression in ADPKD.
Alto Neuroscience receives FDA Fast Track designation for ALTO-101
Calico Life Sciences' investigational treatment for ADPKD receives US FDA Fast Track Designation
Hologic receives FDA clearance and CE mark for new gastrointestinal bacterial assays
Celltrion launches AVTOZMA IV in the United States following FDA approval
Vanda Pharmaceuticals agrees collaborative framework to resolve US FDA disputes
Microbot Medical secures first Japanese patent for Liberty robotic system following FDA clearance
Pharming receives FDA priority review for leniolisib in children with APDS
Renalytix submits CE Mark application for kidneyIntelX.dkd in Europe